Biopharmaceutical company developing treatments for bacterial infections and rare diseases
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Spero Therapeutics, Inc..
The 1 sources with the most insights about Spero Therapeutics, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The host called the company a widely held short and doubted the odds of success for an unspecified drug readout; the cited probability was informal and the trial was not identified.
The host called the company a widely held short and doubted the odds of success for an unspecified drug readout; the cited probability was informal and the trial was not identified.
Other assets that creators frequently mention in the same content as Spero Therapeutics, Inc..
The most active sources covering Spero Therapeutics, Inc. (SLS) on Kazuha are @realmartinshkreli. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 1 AI-extracted insight about Spero Therapeutics, Inc. (SLS) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Spero Therapeutics, Inc. (SLS) most frequently also discuss DNA, INTC, MRVL, LRCX, AMD. See the "Discussed alongside" section above for full asset pages.